专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006054904A2 CONTRAST AGENTS 审中-公开
标题翻译：对比剂
公开(公告)号：WO2006054904A2
公开(公告)日：2006-05-26
申请号：PCT/NO2005000435
申请日：2005-11-21
申请人： AMERSHAM HEALTH AS , LOEVHAUG DAGFINN , ERIKSEN MORTEN , FJERDINGSTAD HEGE B , HEALEY ANDREW
发明人： LOEVHAUG DAGFINN , ERIKSEN MORTEN , FJERDINGSTAD HEGE B , HEALEY ANDREW
IPC分类号： A61K51/04 , A61K49/00 , A61K49/08
CPC分类号： A61K49/0056 , A61K49/0002 , A61K49/0021 , A61K49/0032 , A61K49/085 , A61K49/14 , A61K51/0497
摘要： A contrast agent of the general formula (I): Z 1 -L-V-Z 2 (I) wherein at least one of Z1 and Z2 is present and are equal or different reporter moieties detectable in in vivo imaging of the human or animal body, V is a targeting moiety with binding affinity for areas of collagen formation, L is a covalent bond, a biomodifier or a linker moiety.
摘要翻译：通式（I）的对比剂：其中存在Z1和Z2中的至少一个并且是相同或不同的报告分子部分的Z 1 - 可在体内成像人或动物体内检测到，V是具有对胶原形成区域具有结合亲和力的靶向部分，L是共价键，生物修饰剂或接头部分。

2. 发明申请

WO2005044313A3 CONJUGATES OF ANGIOTENSIN II AND AN IMAGING MOIETY 审中-公开
标题翻译：血管紧张素II和成像环境的关系
公开(公告)号：WO2005044313A3
公开(公告)日：2006-05-11
申请号：PCT/NO2004000335
申请日：2004-11-05
申请人： AMERSHAM HEALTH AS , CUTHBERTSON ALAN , INDREVOLL BAARD , ERIKSEN MORTEN
发明人： CUTHBERTSON ALAN , INDREVOLL BAARD , ERIKSEN MORTEN
IPC分类号： A61K51/08 , A61K38/08 , A61K49/00 , A61P1/16 , A61P9/00 , A61P9/06 , A61P9/10 , A61P11/00 , C07K7/14
CPC分类号： A61K51/08 , A61K38/085 , A61K49/0043 , A61K49/0056 , A61K51/088 , C07K7/14
摘要： The invention comprises pharmaceuticals of formula (I) Z-(L) n -V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis. The novel pharmaceuticals comprise a targeting moiety that binds to a receptor that may or may not be up-regulated and/or over-expressed in the diseased area. The targeting moiety comprises a group which for imaging agents carry a diagnostically imageable moiety, an optional linker group and a peptide moiety. The novel pharmaceutical compounds have high affinity for the Angiotensin Receptors, in particularly for the Angiotensin II (Ang II) type 1 (AT 1 ) receptor.
摘要翻译：本发明包括式（I）Z-（L）-N-V的药物，其中V表示肽，L表示任选的接头，Z表示任选地可携带成像部分M的基团， n表示0或1.药物作为治疗心力衰竭的治疗剂是有活性的，心律不齐，纤维化突出如COPD，肝纤维化和动脉粥样硬化等疾病，也可用作诊断心力衰竭的诊断剂，纤维化疾病如COPD，肝纤维化和动脉粥样硬化等疾病突出。新型药物包含结合受体的靶向部分，所述受体在患病区域中可能或可能不被上调和/或过度表达。靶向部分包含用于成像剂携带诊断可成像部分，任选的连接基团和肽部分的基团。新型药物化合物对血管紧张素受体具有高亲和力，特别是对于血管紧张素II（Ang II）1型（AT 1 H 1）受体。

3. 发明申请

WO2004037336A3 TUBE WITH NON-CIRCULAR INTERNAL CROSS-SECTION 审中-公开
标题翻译：具有非圆形内部交叉部分的管
公开(公告)号：WO2004037336A3
公开(公告)日：2004-09-10
申请号：PCT/NO0300336
申请日：2003-10-08
申请人： AMERSHAM HEALTH AS , ERIKSEN MORTEN
发明人： ERIKSEN MORTEN
IPC分类号： A61M5/00 , A61M5/14 , A61M39/00 , A61M39/08
CPC分类号： A61M5/1408 , A61M5/007 , A61M39/08 , A61M2206/11 , A61M2206/12
摘要： The invention relates to a device and method of using the device for administration of a homogeneous preparation to a patient. More particularly the invention relates to a tube for use in controlled and substantially steady state administration of a segregating particulate dispersion by infusion. The tube of the invention has a non-circular cross-section and is twisted along its centerline.
摘要翻译：本发明涉及使用该装置向患者施用均匀制剂的装置和方法。更具体地，本发明涉及一种用于通过输注控制和基本上稳定地施用分散颗粒分散体的管。本发明的管子具有非圆形横截面，并沿其中心线扭曲。

4. 发明申请

WO2009109569A3 ESTER IMAGING AGENTS 审中-公开
标题翻译： ESTER成像代理
公开(公告)号：WO2009109569A3
公开(公告)日：2010-01-07
申请号：PCT/EP2009052493
申请日：2009-03-03
申请人： GE HEALTHCARE AS , DANIKAS ANTONIOS , ERIKSEN MORTEN
发明人： DANIKAS ANTONIOS , ERIKSEN MORTEN
IPC分类号： A61K49/00
CPC分类号： A61M31/005 , A61B5/0071 , A61B5/0084 , A61B5/4842 , A61B5/6853 , A61K49/0017 , A61K49/0021
摘要： The present invention relates to contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents are esters of 5- aminolevulinic acid (5-ALA). They are useful in the diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, and for follow up of treatment of oesophageal cancer and Barrett's oesophagus. The contrast agents are delivered by particular routes of administration.
摘要翻译：本发明涉及用于食管癌和Barrett食管的光学成像的造影剂。造影剂是5-氨基乙酰丙酸（5-ALA）的酯。它们可用于食管癌和巴雷特食管的诊断，用于跟踪疾病发展进展情况，以及跟进食管癌和巴雷特食管的治疗。造影剂通过特定的给药途径递送。

5. 发明申请

WO02054946A3 ULTRASONIC IMAGING OF PERFUSION USING GASES WITH DIFFERENT PARTIAL PRESSURES 审中-公开
标题翻译：使用不同部分压力的气体进行超声波成像
公开(公告)号：WO02054946A3
公开(公告)日：2002-10-10
申请号：PCT/NO0200015
申请日：2002-01-11
申请人： NYCOMED IMAGING AS , ERIKSEN MORTEN , RASMUSSEN HENRIK
发明人： ERIKSEN MORTEN , RASMUSSEN HENRIK
IPC分类号： A61B8/00 , A61B8/06 , A61K49/22
CPC分类号： A61B8/481
摘要： This invention relates to ultrasound imaging, more specifically to a method of ultrasound investigation involving the use of an ultrasound contrast agent and administration of at least two gases or gas mixtures having different partial pressure of inert gas. The method may be used in assessing blood perfusion in tissue. A timed change of administered gases gives a subsequent change in contrast echogenicity. The gases are preferably administered by inhalation. The invention further relates to gas-microbubble containing ultrasound contrast agents used according to the method, and to kits to be used in assessments of tissue perfusion.
摘要翻译：本发明涉及超声成像技术，更具体地涉及涉及使用超声波造影剂和施用至少两种具有不同分压惰性气体的气体或气体混合物的超声检查方法。该方法可用于评估组织中的血液灌注。给药气体的时间变化给出对比回声反应的随后变化。气体优选通过吸入给药。本发明还涉及根据该方法使用的含有超声波造影剂的气体微泡，以及用于组织灌注评估的试剂盒。

6. 发明申请

WO2012055498A8 METHOD FOR MYOCARDIAL SEGMENT WORK ANALYSIS 审中-公开
标题翻译：心脏分段工作分析方法
公开(公告)号：WO2012055498A8
公开(公告)日：2013-05-30
申请号：PCT/EP2011005198
申请日：2011-10-17
申请人： OSLO UNIVERSITETSSYKEHUS HF , RUSSELL KRISTOFFER , SMISETH OTTO A , ERIKSEN MORTEN
发明人： RUSSELL KRISTOFFER , SMISETH OTTO A , ERIKSEN MORTEN
IPC分类号： G06F19/00 , A61B8/08 , G06K9/00
CPC分类号： A61B5/0044 , A61B5/02028 , A61B5/021 , A61B5/0215 , A61B5/0402 , A61B5/0472 , A61B5/4836 , A61B5/7225 , A61B5/7278 , A61B5/7289 , A61B6/032 , A61B7/00 , A61B8/02 , A61B8/04 , A61B8/065 , A61B8/481 , A61B8/485 , A61B8/5223 , G16H50/20
摘要： The invention relates to medical monitoring apparatuses, methods, and computer programs for determining power or work as a function of time for individual myocardial segments based on strain and pressure measurements. Compared to prior art determinations of determination of mechanical power or work for individual segments, the invention is advantageous as it provides such determination solely from a pressure measurement or estimate and a measurement of strain, preferably by echocardiography, such as speckle tracking ultrasound imaging. This allows a fast, easy and non-invasive determination with high temporal and spatial resolution. A number of indices for segment work can be calculated which can be used as markers for the individual segment function as well as for a selection of patient for CRT.
摘要翻译：本发明涉及用于基于应变和压力测量来确定作为时间的函数的个体心肌节段的功率或工作的医疗监测设备，方法和计算机程序。与现有技术测定机械功率或单个部分的功能的确定相比，本发明是有利的，因为它仅通过压力测量或估计和应变的测量（优选通过超声心动图如斑点跟踪超声成像）来提供这样的确定。这允许以高的时间和空间分辨率进行快速，简单和非侵入性的测定。可以计算多个分段工作的指标，可以将其用作单个分段功能的标记以及CRT的患者选择。

7. 发明申请

WO9949899A3 DIAGNOSTIC IMAGING OF VASCULAR ABNORMALITIES USING VASOMODIFICATION 审中-公开
标题翻译：使用血管造影术诊断血管异常的诊断
公开(公告)号：WO9949899A3
公开(公告)日：2000-02-10
申请号：PCT/GB9901002
申请日：1999-03-31
申请人： NYCOMED IMAGING AS , ERIKSEN MORTEN , OESTENSEN JONNY , FRIGSTAD SIGMUND
发明人： ERIKSEN MORTEN , OESTENSEN JONNY , FRIGSTAD SIGMUND
IPC分类号： A61K49/00 , A61B5/055 , A61B8/06 , A61K49/04 , A61K49/06 , A61K51/04 , A61K51/12 , G06T5/50 , G06T7/00 , A61K123/00
CPC分类号： A61K49/0002 , A61K49/0466 , A61K49/048 , A61K49/06 , A61K51/04
摘要： A method of contrast agent-enhanced imaging involving induction of vasomodification, e.g. by physical or pharmacological means, in which pre- and post-vasomodification images in respect of free-flowing contrast or tracer agent in a substantially steady state distribution are recorded as part of a single imaging sequence and are compared to identify any local variations resulting from changes in vascular volume caused by the vasomodification. Imaging techniques which may be employed include ultrasound imaging, magnetic resonance imaging, X-ray imaging and nuclear tracer techniques such as scintigraphy.
摘要翻译：造影剂增强成像的方法涉及诱导血管扩张，例如，通过物理或药理学手段，将基本上稳定状态分布中的自由流动对比度或示踪剂的血管前和后血管变化图像记录为单个成像序列的一部分，并将其与来自由血管扩张引起的血管体积变化。可以使用的成像技术包括超声成像，磁共振成像，X射线成像和核示踪技术如闪烁扫描。

8. 发明申请

WO2007066119A3 NOVEL IMAGING AGENTS FOR FIBROSIS 审中-公开
标题翻译：新型成像剂进行FIBROSIS
公开(公告)号：WO2007066119A3
公开(公告)日：2008-04-10
申请号：PCT/GB2006004579
申请日：2006-12-07
申请人： GE HEALTHCARE LTD , TOLLESHAUG HELGE , NEWTON BEN , RYDBECK ANNA , CHETTIBI SALAH , ERIKSEN MORTEN
发明人： TOLLESHAUG HELGE , NEWTON BEN , RYDBECK ANNA , CHETTIBI SALAH , ERIKSEN MORTEN
IPC分类号： A61K49/00 , A61K49/10 , A61K49/14 , A61K51/04 , A61K101/02 , A61K103/10
CPC分类号： A61K49/0002 , A61K51/0431 , A61K51/0459
摘要： The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which LOX is upregulated is provided.
摘要翻译：本发明提供了适用于纤维化的非侵入性可视化的新型成像剂。本发明还提供了用于制备显影剂的方法，以及用于所述方法的前体。还提供了包含成像剂和用于制备药物的试剂盒的药物组合物。在另一方面，提供了用于体内成像和用于诊断LOX上调的病症的药物的成像剂的用途。

9. 发明申请

WO2010097698A2 MANAGING FLOW/VOLUME LOOP INFORMATION 审中-公开
标题翻译：管理流量/体积循环信息
公开(公告)号：WO2010097698A2
公开(公告)日：2010-09-02
申请号：PCT/IB2010000481
申请日：2010-02-24
申请人： VOLUSENSE AS , ERIKSEN MORTEN , ENGER OEIVIND
发明人： ERIKSEN MORTEN , ENGER OEIVIND
IPC分类号： A61B5/087
CPC分类号： G06F19/34 , A61B5/087 , A61B5/091
摘要： Embodiments of the present invention provide methods of extracting optimal information from a flow/volume loop concerning the patient's respiratory condition by examining the overall shape of the space under the flow/ volume loop's expiration portion. In some embodiments, this is done with reference to the center of mass of that space. In some embodiments, this is done with reference to the area of that space. Some embodiments are significantly less affected by random/statistical variations and/or noise within the measurement system than existing methods.
摘要翻译：本发明的实施例提供了通过检查流/体积循环的呼出部分下的空间的整体形状来从关于患者的呼吸状况的流量/体积循环中提取最佳信息的方法。在一些实施例中，这是参照该空间的质心进行的。在一些实施例中，这是参照该空间的区域来完成的。一些实施方案比现有方法受到测量系统内的随机/统计变化和/或噪声的影响更小。

10. 发明申请

WO9817324A3 IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS 审中-公开
标题翻译：改进或与对比剂相关
公开(公告)号：WO9817324A3
公开(公告)日：1998-06-25
申请号：PCT/GB9702898
申请日：1997-10-21
申请人： MARSDEN JOHN CHRISTOPHER , NYCOMED IMAGING AS , OESTENSEN JONNY , ERIKSEN MORTEN , FRIGSTAD SIGMUND , RONGVED PAAL
发明人： OESTENSEN JONNY , ERIKSEN MORTEN , FRIGSTAD SIGMUND , RONGVED PAAL
IPC分类号： A61K49/00 , A61K9/107 , A61K9/127 , A61K49/22
CPC分类号： A61K49/223 , Y10S977/928 , Y10S977/929
摘要： Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations include a coadministerable composition comprising a diffusible component capable of inward diffusion into the dispersed gas phase to promote temporary growth thereof. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences in return signal intensity from normal and hypoperfused myocardial tissue respectively.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式